MLF1IP is correlated with progression and prognosis in luminal breast cancer.
Myeloid leukemia factor 1-interacting protein (MLF1IP) has been found to be involved in the progression of several malignancies. The potential correlation between MLF1IP and clinical outcome in patients with luminal breast cancer, however, remains unknown. In the present study, we demonstrated that MLF1IP was significantly upregulated in luminal breast cancer tissue compared with adjacent normal tissue both in validated cohort and TCGA cohort. Upregulated expression of MLF1IP was correlated with more often lymph node metastasis and negative progesterone receptor expression in TCGA cohorts. Kaplan-Meier analysis indicated that patients with high MLF1IP expression had significantly lower overall survival. Moreover, multivariate analysis revealed that high MLF1IP expression was independent high risk factor as well as old age (>60) and distant metastasis. This study provides new insights and evidences that MLF1IP over-expression plays important roles in progression of luminal breast cancer. However, the precise cellular mechanisms for MLF1IP in luminal breast cancer need to be further explored.
['Huang|Du-Ping|DP|', 'Luo|Rong-Cheng|RC|']
D017677:Age Distribution D000368:Aged D000369:Aged, 80 and over D014408:Biomarkers, Tumor D001943:Breast Neoplasms D018797:Cell Cycle Proteins D002681:China D018450:Disease Progression D005260:Female D006657:Histones D006801:Humans D008875:Middle Aged D009361:Neoplasm Invasiveness D009687:Nuclear Proteins D015995:Prevalence D011379:Prognosis D015203:Reproducibility of Results D018570:Risk Assessment D012680:Sensitivity and Specificity D015996:Survival Rate
MLF1IP Prognosis Luminal breast cancer